Baird raised the firm’s price target on Cencora (COR) to $292 from $287 and keeps an Outperform rating on the shares. The firm said they delivered another solid report, guided favorably, and announced a very intriguing MSO deal in a new field for distributors; retina care specialists.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR: